Acute Respiratory Distress Syndrome Market Insights report from DelveInsight provides a thorough understanding of the Acute Respiratory Distress Syndrome Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Acute Respiratory Distress Syndrome Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.
Acute Respiratory Distress Syndrome Overview
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible.
Download Sample Report- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market
Regions covered in the report
Key highlight of the Acute Respiratory Distress Syndrome Market Report
Acute Respiratory Distress Syndrome Epidemiology Insights
Acute Respiratory Distress Syndrome is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.
Acute Respiratory Distress Syndrome Epidemiology Segmentation in the 7MM
Do you want to know more information related to report? If yes, visit here- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market
Acute Respiratory Distress Syndrome Treatment Market
Acute respiratory distress syndrome treatment is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management.
Acute Respiratory Distress Syndrome Market Insights
In Acute respiratory distress syndrome, the evolution of systemic and pulmonary inflammation in the 1st week of mechanical ventilation determines the physiologic progression (resolving vs unresolving) and the outcome of the disease. Glucocorticoids as end-effectors of the hypothalamic-pituitary-adrenal axis are the most important physiologic inhibitors of inflammation, affecting hundreds of genes involved in stress-related homeostasis. At the cellular level, glucocorticoids exert their effects by activating cytoplasmic heat shock protein-complexed glucocorticoid receptors, which in turn, interact with activated nuclear factor-κB to prevent DNA binding and subsequent transcriptional activity.
Acute Respiratory Distress Syndrome Market Size
The Acute Respiratory Distress Syndromemarket size in the seven major markets was approximately USD 1,354.7 million in 2021, which is further expected to increase by 2032
Acute Respiratory Distress Syndrome Market Forecast
Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. Other treatment options, which the patients with ARDS are subjected to generally include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less-abled to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.
Acute Respiratory Distress Syndrome Emerging Therapies
Expected launch of emerging therapies, such as EB05 (Edesa Biotech/Light Chain Bio), DB- 001 (Direct Biologics), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys/Healios), Alteplase (Boehringer Ingelheim/Genentech), and Lucinactant (Windtree Therapeutics) etc. shall further create a positive impact on the market.
Request Sample Report- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market
Table of Content
1. Key Insights
2. Report Introduction
3. Acute Respiratory Distress Syndrome Market Overview at a Glance
4. Acute Respiratory Distress Syndrome Market: Future Perspective
5. Executive Summary of Acute Respiratory Distress Syndrome
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Off-Label Therapies for ARDS
11. Emerging Drugs
12. Acute Respiratory Distress Syndrome: Seven Major Market Analysis
13. Key Opinion Leaders’ Views
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Reimbursement and Market Access
18. Unmet Needs
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Do you have any query related to report? If yes, visit here- https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/